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The Role of Fas in Autoimmune Diabetes
Alexander V. Chervonsky,*§‖ Yi Wang,³§‖ contains a ªdeathº domain in its cytoplasmic region that
is able to transduce an apoptotic signal upon cross-F. Susan Wong,* Irene Visintin,*
linking by Fas ligand (FasL) (reviewed by Nagata andRichard A. Flavell,*²
Golstein, 1995) or anti-Fas antibodies (Trauth et al.,Charles A. Janeway, Jr.,*²#
1989; Yonehara et al., 1989).and Louis A. Matis³#
Both Fas and FasL are expressed by activated T lym-*Section of Immunobiology
phocytes (Klas et al., 1993; Russell et al., 1993; Gilette-Yale University School of Medicine
Ferguson and Sidman, 1994; Vignaux and Golstein,²Howard Hughes Medical Institute
1994; Alderson et al., 1995; Dhein et al., 1995). Thus,310 Cedar Street
when a Fas-expressing activated T cell meets anotherNew Haven, Connecticut 06510
T cell (or different type of cell) that has FasL on its³Alexion Pharmaceuticals
surface, it undergoes apoptosis (Russell et al., 1993;25 Science Park
Alderson et al., 1995; Dhein et al.,1995). This mechanismNew Haven, Connecticut 06511
is believed to be involved in the regulation of the size
of the pool of activated T cells after immunization (Vig-
naux and Golstein, 1994) and in protection of immune
Summary privileged sites like the eye (Griffith et al., 1995) or testis
(Bellgrau et al., 1995). Also, tumor cells expressing FasL
Immunologically privileged sites express Fas ligand have been shown to be resistant to T cell attack (Hahne
(FasL), which protects them from attack by activated et al., 1996; Strand et al., 1996).
T cells that express Fas and die upon contact with We sought to investigate the ability of ectopically ex-
FasL. In an attempt to protect nonobese diabetic mice pressed FasL to interfere with autoimmune destruction
(NOD) from autoimmune diabetes, we made FasL of target tissue cells. The nonobese diabetic (NOD) strain
transgenic NOD mice using the b cell-specific rat insu- of mice serves as a model for human insulin-dependent
lin-1 promoter. Surprisingly, these transgenic mice diabetes mellitus (IDDM). The autoimmune process in
showed heightened sensitivity to diabetogenic T cells, these animals is characterized by stepwise development
which was due to self-destruction of b cells upon T with two proposed checkpoints (AndreÂ et al., 1996). The
cell-mediated induction of Fas. Fas-negative NOD lpr/lpr first (around 5 weeks) is characterized by infiltration of
animals were resistant to diabetogenic T cells and to the islets of Langerhans with lymphoid and myeloid cells
spontaneous diabetes. Thus, induction of Fas expres- called insulitis, and the second (around 12 weeks) is
sion on b cells and their subsequent destruction con- marked by massive destruction of insulin-producing b
cells, leading to diabetes. T cells have been shown tostitutes the main pathogenic mechanism in autoim-
play a crucial role in the disease (for review, see Tischmune diabetes.
and McDevitt, 1996). In theory, expression of FasL by
b cells might lead to the destruction of activated autore-Introduction
active Fas-expressing T cells and thus protect the islets.
Such islets could be used for transplantation into dia-Adaptive immunity provides protection from the multi-
betic recipients in order to normalize insulin produc-tude of exogenous infectious agents, which are recog-
tion. A recent study involving transplantation of FasL-nized by clonal receptors expressed by T and B lympho-
expressing myoblasts together with pancreatic islets
cytes. The diversity of clonal receptors is based on
(Lau et al., 1996) has supported the feasibility of this
random combinations of receptor gene segments pro-
approach.
duced during T and B cell maturation. For that reason,
To our surprise, some animals expressing FasL in
clones of lymphocytes with receptors recognizing self pancreatic islets showed higher rates of spontaneous
antigens are constantly produced and must be elimi- diabetes, and all transgenic animals were more sensitive
nated or suppressed by regulatory mechanisms. A sub- to diabetogenic T cells than their nontransgenic lit-
stantial breakthrough in understanding the regula- termates. Further studies revealed that b cells are in-
tory mechanisms in autoimmunity came from studies of duced to express Fas by T cells. This suggested that
mice with lpr (lymphoproliferation) and gld (generalized FasL transgenic b cells were committing suicide (or frat-
lymphoproliferative disease) mutations. Both mouse ricide) upon induction of Fas. More importantly, we
strains demonstrate expansion of lymphocytes with an found that the ability to upregulate Fas is acquired by
unusual surface phenotype and a variety of autoimmune b cells during the natural course of diabetes in NOD
reactions. lpr and gld were found to be complementary mice, indicating that Fas-mediated apoptosis of b cells
mutations of a receptor and its ligand (Allen et al., 1990; may be the major mechanism for decrease in insulin
Watanabe-Fukunaga et al., 1992a; Lynch et al., 1994; production and establishment of diabetes.
Takahashi et al., 1994). The receptor appeared to be Fas
protein (CD95), a member of the TNF-receptor family. It Results and Discussion
RIP-FasL Transgenic Animals§To whom correspondence should be addressed.
We prepared a construct (Figure 1A) in which FasL ex-‖ These authors made equal contributions to this paper.
# These authors made equal contributions. pression is driven by the rat insulin promoter-1 (RIP),
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Figure 1. RIP-Fasl Transgene Construction
and Evaluation of Expression
(A) Fasl cDNA was introduced into a construct
containing RIP promoter and MHC class II Ea
chain exons 3 and 4 by excision of B7 cDNA
(1) and its replacement with Fasl cDNA (2 and
3) by blunt-end ligation. HinPI fragment was
used for microinjections. Boxes represent ex-
ons. Alsoshown are positions of primers used
for transgene screening (a) and mRNA ex-
pression (b).
(B) RT-PCR was used to compare expression
of FasL between transgenic strains. Insulin-1
primers were used as an estimate of b cell-
specific mRNA. Densitometric analysis (bot-
tom of the left panel) demonstrates relatively
high FasL expression by RIP-FasL-31 trans-
genic b cells compared to RIP-FasL-24 and
RIP-FasL-32. The quantities of PCR products
for both transgenic FasL and insulin were
within linear portions of the template titration
curves (right panel).
limiting gene expression to b cells (Hanahan, 1985). We Diabetes in RIP-FasL Transgenic Mice
To determine if transgene expression would alter thechose to inject the DNA into oocytes of NOD mice di-
rectly, rather than breed conventional transgenic mice natural course of diabetes, the RIP-FasL mice together
with negative littermates were observed for a 25-weekback to the NOD background in order to eliminate any
undesired contribution of non-NOD genes to the genetic period, and the incidence of diabetes was followed. Sur-
prisingly, the incidence of diabetes in different strainsbackground of these mice. Several founders of NOD-
RIP-FasL mice were obtained. Expression of functional varied dramatically (Figure 2a). While normal NOD mice
start to develop diabetes around 12 weeks of age, inFasL protein could be demonstrated in a thymocyte
killing assay, in which overnight coincubation of B6 thy- some transgenic lines disease was accelerated. Thus,
one founder, NOD-RIP-FasL-25, became diabetic at themocytes with b cells isolated from transgenic animals
but not from nontransgenic littermates led to apoptosis age of six weeks and therefore did not produce progeny.
The majority (but not all) of the mice of another strain,of thymocytes (data not shown). FasL expression was
also determined by reverse transcription-polymerase NOD-RIP-FasL-24, turned diabetic starting from week
10. NOD-RIP-FasL-32 showed no difference in inci-chain reaction (RT-PCR) (Figure 1B).None of the animals
were diabetic as determined by blood glucose level at dence of diabetes compared with nontransgenic NOD
littermates, while NOD-RIP-FasL-31 were relatively re-the time of sacrifice. Therefore, insulin was used to stan-
dardize the amount of b cell-specific cDNA for compari- sistant to diabetes, with only a few animals showing
glucosuria at 25 weeks.son between samples. These reactions produced prod-
ucts of 620 bp and 357 bp for Fasl transgene and insulin, The histological examination of pancreatic tissues
from these mice revealed that in diabetic NOD-RIP-respectively (Figure 1B, left panel). To ensure that the
amount of PCR product generated from actual cDNA FasL-25 and NOD-RIP-FasL-24 mice, islets were signifi-
cantly damaged, with very little insulin remaining (Fig-could be quantitatively measured, we performed simul-
taneous titration of templates in 1021 steps (Figure 1B, ures 2b and 2c). In contrast, NOD-RIP-FasL-31 islets
(25 weeks old) were well preserved, with infiltration oc-right panel). Transgenic strain NOD-RIP-FasL-31 was
found to express considerably more Fasl mRNA than curing in some islets mostly in the form of periinsulitis
(Figures 2d±2f). Age-matched nontransgenic NOD miceNOD-RIP-FasL-24 and NOD-RIP-FasL-32.
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Figure 3. Acceleration of Diabetes in RIP-FasL-32 Tg Mice Inocu-
lated with 107 CD81 G9C8 T Cell Clone
Mice were irradiated (725 rad) on day 21, and cells were injected
IV on day 0. Blood glucose levels were determined daily. Open
symbols indicate transgenics, closed symbols indicate non-
transgenic littermates.
commit suicide upon up-regulation of Fas. NOD-RIP-
FasL-31 with a higher level of FasL expression were able
to resist incoming infiltrating T cells, but the resistance
weakened with the aging of mice (Figure 2a).
b Cells Can Express Fas
The demonstration that Fas can in fact be expressed by
b cells came from the following experiments. Cytotoxic
CD81 islet-specific T cell clones have been shown pre-
viously to cause severe damage to b cells, leading to
hyperglycemia and rapid death following their adoptiveFigure 2. Consequences of FasL Expression in Pancreatic b Cells
transfer to irradiated NOD or NOD-scid recipients (Na-(a) Cumulative incidence of diabetes in non-Tg NOD and FasL-Tg
strains 24, 31, and 32. Mice were followed for 25 weeks with weekly gata et al., 1994; Wong et al., 1996). When such T cells
measurements of urine glucose. The number of observed animals (Wong et al., 1996) were injected into irradiated NOD
is shown in parentheses. and NOD-RIP-FasL-32 transgenic mice, substantial ac-
(b±h) Islets in strains with accelerated diabetes were largely de-
celeration of diabetes was observed in the mice ex-stroyed ([b], strain 25; [c], strain 24), as seen by staining for insulin.
pressing FasL compared to nontransgenic littermatesFounder 25 was 5 weeks old; RIP-FasL-Tg 24 animal was 10 weeks
(Figure 3). Histologically, b cells in transgenic animalsold. In resistant strain 31 (25-week-old animal), the islets appear
normal ([d], insulin staining) and with little infiltration with CD41 (e) were severely damaged (data not shown). Furthermore,
and CD81 (f) T cells, while the nontransgenic 25-week-old littermate the same accelerated disease was obtained with all
has severe infiltration with both CD41 (g) and CD81 (h) cells. NOD-RIP-FasL transgenic strains tested (Table 1). The
diabetes-inducing potential of the CD81 T cells was
overwhelming, so that even otherwise protected NOD-demonstrated massive infiltration of the islets with CD4
RIP-FasL-31 mice showed accelerated diabetes. Theseand CD8T cells (Figures 2g and 2h). The islet destruction
results suggested that the underlying mechanism forin transgenic mice with accelerated diabetes ruled out
diabetes induction must be uniform for all RIP-FasLthe possibility of nonspecific inhibition of insulin produc-
transgenic strains. Presumably, the CD81 T cells pro-tion, as has been reported for another RIP-driven
duced a factor(s) inducing Fas expression by the b cells.transgene (Allison et al., 1991).
Engagement of FasL expressed by transgenic b cellsAlthough intact normal islets do not express Fas (an
resulted in b cell killing.observation based on immunohistochemical examina-
tion of the NOD islets as well as FACS staining of isolated
Table 1. Diabetes in NOD and NOD-FasL Transgenic Mice afterb cells performed prior to the beginning of the transgene
Injection of CD81 Cell Clone*construction), these results lead us to suspect that b
cells could be induced to express Fas by infiltrating Day after Transfer
inflammatory cells. If such Fas-expressing islets also
Mouse Strain Day 1 Day 2 Day 3 Day 4
express the ligand for Fas, the effect would be destruc-
Non-tg NOD 0/7 0/7 1/7 6/7tion of b cells by suicide or fratricide. The differences
tg 24 NT 2/4 4/4between different FasL transgenic strains would then
tg 31 0/3 1/3 3/3
most probably reflect the differences in the levels of
CD81 G9C8 T cell clones (107 cells) were injected IV on day 0 intoexpression of FasL. b cells expressing low levels of
animals irradiated (725 rad) on day 21. NT, not tested.FasL, such as NOD-RIP-FasL-24, do not have enough
* Diabetic/total injected ratio.
FasL to destroy all incoming T cells but are able to
Cell
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Table 2. Kinetics of Diabetes in Young and Old NOD Mice after
Injection of CD81 T Cell Clone*
Day after Transfer
Age of Mice (weeks) Day 2 Day 3 Day 4 Day 5
4±5 0/7 0/7 4/7 6/7
8 0/3 2/3 2/3 3/3
121 3/6 4/6 5/6 6/6
TGNF-H3 cells (107) were injected IV into irradiated NOD animals of
different ages.
* Diabetic/total injected ratio.
correlation between the ability to express Fas and the
natural course of diabetes in NOD mice. IDDM in NOD
mice is obviously a chronic illness marked by stepwise
development with characteristic checkpoints (AndreÂ et
al., 1996). At about 12 weeks of age, the insulitis turns
Figure 4. Fas-Negative NODlpr/lpr Mice Are Resistant to Islet-Spe-
into destructive diabetes (AndreÂ et al., 1996). Could Fascific CD8 T Cells
up-regulation be involved in this process? In order toTGNF-H3 CD81 T cells (7.5 3 106) were transferred IV into NODlpr/lpr
investigate the importance of Fas, we performed the(open symbols) or NOD1/1 littermates (closed symbols).
following experiments. First, NOD mice of different ages
were injected with the CD81 T cell clone TGNF-H3 (TableAssuming that this scenario is true, then mice with a
2). The results showed clearly that the sensitivity to cyto-genetic defect in Fas expression (lpr/lpr) (Murphy and
toxicity by CD81 T cells is age dependent; older miceRoths, 1978; Watanabe-Fukunaga et al., 1992a; Adachi
have a more rapid increase in blood glucose level thanet al., 1993) would be resistant to the diabetes-inducing
younger animals. Several factors could account for thiseffect of these T cells. To test this hypothesis, NOD mice
phenomenon, including better homing of the CTL to thewere crossed with MRLlpr/lpr mice, and the lpr gene was
pancreas owing to higher expression of the relevantbackcrossed to NOD for six generations and then inter-
antigen, preexisting damage in older animals, or morecrossed. NOD1/1 and NODlpr/lpr mice were injected with
rapid up-regulation of Fas. To distinguishbetween thesethe islet-specific CD81 T cell clone TGNF-H3. NODlpr/lpr
possibilities, we conducted histological examination ofmice were resistant to the diabetogenic effects of the
the pancreata from young and older animals. In such atransferred T cells. None of 5 NODlpr/lpr mice in the first
kinetic experiment, in which irradiated NOD mice of 4±5experiment were diabetic 20 days postinjection, at
weeks and 121 weeks of age were injected with equalwhich time point they were sacrificed, whereas NOD1/1
numbers of the CD81 T cells and sacrificed at differentlittermates became diabetic within 6 days (Figure 4). In
time points, it was demonstrated that CD81 T cells couldthe second experiment, NOD lpr/lpr recipients with normal
be detected in both young and older animals alike, sug-blood glucose levels were sacrificed 3 days after their
gesting that homing was similar in both age groupsFas-sufficient littermates became diabetic. The results
(Figure 6). Furthermore, in the 12-week-old group, Fasof histological examination of their pancreata are shown
on islet cells could be detected by staining with thein Figure 5. The lpr mutation did not affect homing of
monoclonal antibody JO2 on day 2 after transfer of thethe TGNF-H3 cells into the pancreas. Vb61-infiltrating
T cells (Figures 6A[e] and 6B[d]), while in younger ani-cells were found in the islets of both NOD and NODlpr/lpr
mals it was undetectable even on day 4 (Figure 6A[a±c]).mice (Figure 5d), but b cells in the NOD mice were more
Thus, the ability to rapidly upregulate Fas is acquiredseverely damaged than in NODlpr/lpr (Figures 5g±5i). Fas
with age. It should be stressed, however, that younginduction was obvious in the NOD islet cells (Figure
RIP-FasL transgenic NOD mice showed accelerateddia-5h). In contrast, in NODlpr/lpr animals insulin production
betes following CD81 T cell transfer, suggesting thatremained high (Figures 5c and 5f), and Fas staining was
young NOD mice can be induced to express Fas onassociated only with Fas1 infiltrating CD81 T cells (Fig-
their b cells to levels that make them sensitive to FasLures 5b and 5e). Fas expression by the adoptively trans-
expressed by b cells, but which are too low to be de-ferred CD81 T cells was confirmed by FACS analysis
tected by immunohistochemical staining. Similarly, up-(Figure 5a). Thus, the pathogenic effect of the CD81 T
regulation of Fas by an insulinoma cell line b-TC1 incells is primarily via the Fas-mediated pathway. It should
vitro was documented by RT-PCR, while the levels ofbe noted, however, that the transferred T cells are able
Fas on cell surface remained undetectable by stainingto produce perforin and TNFa (Wong et al., 1996), as
with monoclonal antibodies (Yamada et al., 1996).well as FasL (data not shown). This might explain the
Finally, the importance of Fas in the natural course offact that some destruction of the NODlpr/lpr islets was
diabetes was confirmed by determination of the inci-observed (Figure 5c). Presumably, cytotoxic mecha-
dence of spontaneous diabetes in the NODlpr/lpr animalsnisms other than signaling through Fas may contribute
compared to NOD1/1 littermates. Based on the data ofto b cell damage.
T cell transfer experiments, one would anticipate that
Fas-negative NODlpr/lpr mice would be resistant to spon-The Role of Fas in the Natural Course of Diabetes
taneous diabetes, given that Fas-mediated apoptosis isSince Fas-mediated destruction of b cells has been
demonstrated by the above experiments, we sought a a major mechanism of b cell destruction. In fact, none
Fas and Progression of Autoimmune Diabetes
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Figure 5. Immunohistochemical Examination of Pancreata from NOD and NODlpr/lpr Mice Injected with T Cell Clone TGNF-H3
(a) Injected T cells expressed Fas, as shown on the left panel (1, control; 2, anti-Fas), and both CD8 and Vb6 (right panel).
(b±i) Serial cryostat sections of pancreata isolated from NOD1/1 mice on the day of diabetes onset (g±i), and from NODlpr/lpr isolated 3 days
after the last NOD1/1 mouse became diabetic (b±f), were stained for insulin (c, f, and i), anti-Vb6 TCR (d and g), and Fas (b, e, and h).
of the NODlpr/lpr mice had elevated glucose levels at the experiments (Wong et al., 1996). The NIT-1 insulinoma
cell line (Hamaguchi et al., 1991) became sensitive toend of a 25-week observation period, while Fas-suffi-
cient littermatesshowed over 75%incidence of diabetes lysis by FasL-expressing fibroblasts after treatment with
interferon-g (data not shown), which has also been re-(Figure 7).
Taken together, our data suggest that Fas-mediated ported to induce Fas on other cell types (Yonehara et
al., 1989; Watanabe-Fukunaga et al., 1992b; Takahashidestruction of b cells is indeed a part of the natural
diabetogenic process in NOD mice. As defined by et al.,1995). Also, IL-1 has been implicated in stimulation
of Fas expression on human (Stassi et al., 1996) andMathis, Benoist, and theircolleagues (AndreÂ et al., 1996),
development of IDDM in NOD mice is characterized by mouse (Yamada et al., 1996) b cells in vitro. It is, of
course, possible that a combination of cytokines maytwo checkpoints. The first is theonset of insulitis (around
5 weeks) with no significant damage to the islets; the be more potent in Fas induction than individual factors.
TGFb has been identified as an active factor producedsecond is diabetes (around 12 weeks) with islet destruc-
tion and hyperglycemia. The acquisition of the ability to by T cell clones that protect from diabetes (Han et al.,
1996). Whether this cytokine is able to inhibit Fas expres-upregulate Fas to detectable levels correlates well with
the time of this second checkpoint. Thus, the severity sion or activity, or whether it neutralizes Fas induction
by other cytokines, remains to be studied. At least 15of islet destruction may be attributed to the induction
of Fas on the b cells. Fas-dependent cytotoxicity may genes have been reported to be responsible for suscep-
tibility of NOD mice to autoimmune diabetes (Wicker etbe elicited both by CD8 T cells (Rouvier et al., 1993) and
by Th1-type CD4 T cells (Ramsdell et al., 1994). Both al., 1995; Tisch and McDevitt, 1996; Vyse and Todd,
1996). Whether any of them influence Fas expression,CD4 and CD8 cellsare involved in developmentof diabe-
tes (summarized in Tisch and McDevitt, 1996, and AndreÂ and what exactly determines the timing of Fas induction
around 12 weeks of age, needs to be determined. Pre-et al., 1996). Recently published data suggest that the
shift of the autoimmune response in NOD mice toward liminary experiments (data not shown) demonstrated
that NOD-RIP-FasL transgenic mice crossed to mice ofTh1 correlates with severe pathology (Lenschow et al.,
1996). Our preliminary experiments suggest that Th1 different genetic backgrounds remain more sensitive to
CD81 cells than their nontransgenic littermates, arguingcytokines, specifically interferon-g, may be involved in
the stimulation of Fas expression by b cells. This cyto- that Fas induction does not require the entire NOD back-
ground. It is also noteworthy that Fas function in NODkine is produced by the CD8 cells used in our in vivo
Cell
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Figure 6. Fas Is Induced in Pancreatic b Cells
in an Age-Dependent Manner
(A) [a±c] In the young (# 5 weeks) NOD mice
injected with 107 TGNF-H3 cells, Fas expres-
sion is associated primarily with CD81 cells
and not with insulin-producing b cells. Serial
cryostat sections were from an animal sacri-
ficed on day 4 after transfer. [d±f] In contrast,
in the older ($ 12 weeks) NOD mice from the
same experiment, Fas is detected in islet cells
at day 2. Staining was for CD8 [a and d], Fas
[b and e], and insulin [c and f].
(B) In 12-week-old NOD mice, Fas [b and d]
is associated with effector CD81 T cells (CD8
staining shown in [a] and [c]) on day 1 [a and
b] and with both effector cells and islet cells
on day 2 [c and d].
mice is normal, as thymocytes of NOD mice were killed benign infiltration todetrimental destruction of the islets.
Fas-mediated apoptosis appears to be the predominantby FasL-expressing fibroblasts (gift of I. N. Crispe, Yale
University) to the same extent as B6 thymocytes mechanism in T cell-mediated damage to insulin-pro-
ducing b cells. It is important to determine whether in-(73.7% 6 4.3% and 69.9% 6 4.8%, respectively).
The role for Fas±FasL interaction in autoimmunity duction of Fas and Fas-mediated apoptosis of target
cells is involved in human IDDM as well as other T cell-(based on the inability to control autoreactive T cells
owing to abnormalities in these two molecules) has been mediated autoimmune disorders.
Our findings also put certain constraints on the useappreciated for lymphoproliferative disorders in humans
(Fisher et al., 1995; Rieux-Laucat et al., 1995) and ani- of FasL-expressing tissues for transplantation, the idea
that led to the present study. It has been reported thatmals. Our studies have revealed a second major mecha-
nism of autoimmunity involving Fas, i.e., induction of FasL expression by grafted fibroblasts may stimulate
their destruction (Yagita et al., 1996), but whether or notFas expression on target cells and their subsequent
destruction. Expression of Fas by pancreatic b cells has the destruction was caused by induction of Fas on the
graft has not been tested. Generation of Fas-negativebeen shown tohave a major influence on thesusceptibil-
ity of NOD mice to diabetes and to be associated with FasL-positive tissues may constitute a better approach
for construction of indestructible grafts.a critical transformation in the course of diabetes from
Experimental Procedures
Transgene Construction and Evaluation
of Transgene Expression
The RIP-Fasl DNA constuct was prepared by subcloning Fasl cDNA
(gift of Dr. I. N. Crispe, Yale University) into pSRa(N1) vector (Hughes
and Crispe, 1995). The FasL insert was excised by XbaI and SacI
enzymes, gel purified, and the ends were blunted by T4 DNA poly-
merase (GIBCO±BRL, Grand Island, NY) treatment. Human B7 cDNA
insert was removed from the RIP-Ea-B7 construct (Lo et al., 1988;
Guerder et al., 1994) by XhoI enzyme digestion, the vector was
gel purified, and the ends were blunted by Klenow fragment DNA
polymerase (GIBCO±BRL) treatment, dephosphorylated, and the
FasL insert was subcloned into this vector. The orientation of the
insert was verified by restriction analysis, and the accuracy of se-
quences at the 59 and 39 ends of FasL coding region was verified
Figure 7. Fas-Deficient NODlpr/lpr AnimalsAre Resistant to Spontane- by sequencing. DNA was prepared for injection by purification of
ous Diabetes the 3.75 kb HinPI fragment. Oocyte microinjections were performed
by Yale DERC Transgenic Facility. Primers used for Tg screeningIncidence of diabetes in NOD and NODlpr/lpr mice. Animals were fol-
lowed for 25 weeks with weekly measurements of urine glucose. were forward RIP 5-9CAAGACTCCAGGGATTTGAGGGA-39 and re-
verse FasL 59-CTTTTAAAGCTTATACAAGCCGAAAAAGGT-39. TwelveThe number of observed animals is shown in parentheses.
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